The Wnt signaling pathway is a robust regulator of skeletal homeostasis. Gain-of-function mutations promote high bone mass, whereas loss of Lrp5 or Lrp6 co-receptors decrease bone mass. Similarly, mutations in antagonists of Wnt signaling influence skeletal integrity, in an inverse relation to Lrp receptor mutations. Loss of the Wnt antagonist Sclerostin (Sost) produces the generalized skeletal hyperostotic condition of sclerosteosis, which is characterized by increased bone mass and density due to hyperactive osteoblast function. Here we demonstrate that prostaglandin E 2 (PGE 2 ), a paracrine factor with pleiotropic effects on osteoblasts and osteoclasts, decreases Sclerostin expression in osteoblastic UMR106.01 cells. Decreased Sost expression correlates with increased expression of Wnt/TCF target genes Axin2 and Tcf3. We also show that the suppressive effect of PGE 2 is mediated through a cyclic AMP/PKA pathway. Furthermore, selective agonists for the PGE 2 receptor EP2 mimic the effect of PGE 2 upon Sost, and siRNA reduction in Ptger2 prevents PGE 2 -induced Sost repression. These results indicate a functional relationship between prostaglandins and the Wnt/b-catenin signaling pathway in bone. This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration which stipulates that, once placed in the public domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.
Introduction
There remains considerable effort dedicated toward understanding the signaling pathways that promote skeletal anabolism. Prostaglandins (PG), such as prostaglandin E 2 (PGE 2 ), mediate osteoprogenitor proliferation [1, 2, 3] and differentiation [4, 5] . Mechanical loading in vitro and in vivo induces expression of the enzyme responsible for PG synthesis, COX-2 [6, 7, 8] , whose function is required for load-induced bone formation [9, 10] . Similarly, PG administration in vivo increases bone mass via periosteal and endosteal responses [11] . Further, inhibition of PG synthesis delays fracture healing [12, 13] and promotes the formation of non-unions [14, 15] , whereas localized PGE 2 enhances bone healing [16, 17, 18, 19] .
Osteoblast differentiation is also regulated by the Wnt signaling pathway [20] . Binding of Wnt ligands to a complex of Frizzled and Lrp5 or Lrp6 co-receptors promotes the stabilization of the transcription factor b-catenin, formation of a complex with TCF/ LEF, and induction of Wnt target genes like Axin2 and Tcf3 [21, 22] . Activating mutations in Lrp5 cause high bone mass [23, 24] , whereas Lrp5 deletion decreases bone mass [25, 26] and prevents load-induced bone formation [27] . Control of Wnt signaling involves sequestration of Wnts by soluble decoy receptors like sFRPs [28, 29] , or Lrp5 antagonists, like Dkk1 and Sclerostin.
Deletion of the gene encoding Sclerostin (Sost) causes a rare sclerosing bone dysplasia, sclerosteosis (OMIM ID 269500) in both humans and murine knockout models [30, 31, 32, 33] ; a related disease, van Buchem's disease (OMIM ID 239100), is caused by a distal noncoding deletion that removes regulatory elements required for the transcriptional of the Sost gene in adult bone [32] . Both sclerosteosis and van Buchem disease are characterized by general skeletal hyperostosis owing to hyperactive osteoblast activity. In contrast, over-expression of Sost causes osteopenia [34, 35] and limb deformities [36] . Mechanistically, Sclerostin was initially characterized as a BMP antagonist [34, 37, 49] , but more recent reports recognize it as a potent Wnt antagonist that binds to Lrp5 and Lrp6 [38, 39, 40, 41] to increase the rate of receptor internalization [42] . Keller and Kneissel showed that PTH reduces Sost expression via PKA [43] , as did Bellido et al. [44] , and we have previously demonstrated that the regulatory element ECR5 contained within the van Buchem deletion region is necessary for bone-specific Sost expression in transgenic mice [35] , and confers PTH responsiveness, in vitro [45] . Recently, we have also shown that a Sost null mutation partially rescues the Lrp6 +/2 skeletal phenotype in Sost 2/2 ;Lrp6 +/2 animals [36] . Whereas both prostaglandins and Wnt signaling have parallel functions during bone anabolism, there is limited evidence for cross-talk between these two signaling pathways in pre-osteoblasts and in transformed cells. In this study, we examined the influence of PGE 2 on Sclerostin transcription and Wnt signaling, in osteoblastic cells. We demonstrate that prostaglandin E 2 , a longrecognized regulator of osteoblast and osteoclast formation activity, decreases Sost expression and thereby increases Wnt signaling in osteoblastic cells. We also show that PGE 2 transcriptional effect on Sost is mediated through the EP2 receptor (Ptger2) and cAMP, and involves mitigation of endogenous BMP and Mef2 signaling. These results attribute a novel function of prostaglandins in the regulation of Wnt signaling via suppression of the Wnt antagonist Sclerostin.
Results

Prostaglandin E 2 decreases Sost transcription
Although both prostaglandins and Wnt signaling have been characterized as robust regulators of skeletal formation and homeostasis [9, 24, 46, 47, 48] , there is sparse evidence whether there is direct interaction between these pathways. To that end, we first sought whether PGE 2 demonstrated an effect upon the transcription of Sclerostin. To test this, UMR106.01 cells were chosen, as they phenotypically resemble mature osteoblasts and express high levels of Sost [43, 50, 51] . UMR106.01 cells were treated with 5 nM-5 mM PGE 2 for 3 hours, after which time RNA was collected and analyzed via quantitative PCR (qPCR) for Sost expression. There was no influence of 5 nM PGE 2 on Sost expression, while there was steady and progressive decrease in Sost levels upon 50 nM-5 mM PGE 2 treatment ( Figure 1A ). This inhibitory effect upon Sost was not observed when cells were treated with another osteotropic prostaglandin, PGF 2a (5 nM-5 mM; data not shown). The inhibitory effect of PGE 2 was rapid, with statistically significant suppression of Sost observed after one hour of treatment, and this was maintained throughout 24 hours of culture ( Figure 1B) .
Prostaglandin E 2 influences Wnt signaling without affecting Dkk1
Functional decrease in the expression of the Wnt antagonist Sost should effectively increase markers of b-catenin/TCF signaling, such as Axin2 and Tcf3. To that end, we observed that PGE 2 , in the same dosing range that decreased Sost, significantly increased Axin2 and Tcf3 expression after 24 hour culture (Figure 2A) , suggesting that PGE 2 -induced decreases in Sost removed a suppressive effect of endogenous Wnt antagonists upon osteoblast function. Dickkopf1 (Dkk1) inhibits Wnt signaling in the same manner as does Sclerostin [42] . Whereas 50 nM-5 mM PGE 2 dramatically reduced Sost transcript and protein (not shown) levels, PGE 2 had no effect on Dkk1 transcript ( Figure 2B ) nor its protein ( Figure 2C ) expression, suggesting that Sost repression is the primary mechanism of enhanced Wnt signaling in response to PGE 2 treatment.
PGE 2 decreases Sost through cAMP-dependent mechanisms
UMR 106.01 cells express all four classes of PGE 2 receptors (EP1-EP4, encoded by Ptger1-Ptger4; Figure 3A ), which are linked to the synthesis or mobilization of cAMP and Ca 2+ i . EP2 and EP4 increase cAMP levels, while EP1 increases Ca 2+ i through a PLCdependent mechanism; EP3 increases Ca 2+ i and decreases cAMP [52] . To define which receptor(s) are responsible for mediating the suppressive effects of PGE 2 upon Sost, UMR 106.01 cells were treated with 5 mM PGE 2 in the presence of antagonists of protein kinase A (H-89, 2.5 mM) or phospolipase C (U73122, 10 mM) for 3 hours, after which time total RNA was collected and analyzed for Sost levels. In the absence of PGE 2 , inhibition of PLC/IP 3 / Ca 2+ i signaling decreased basal Sost levels ( Figure 3B ), suggesting that release of intracellular calcium is important for maintaining Sost expression. In the presence of PGE 2 , the addition of H-89 appeared to attenuate PGE 2 -induced Sost suppression ( Figure 3B ) although this did not reach statistical significance (p,0.1 versus 5 mM PGE 2 alone). In contrast, the addition of PGE 2 to U73122-treated cells demonstrated no change compared to U73122 alone. The role of cAMP and Ca 2+ i mobilization in suppressing Sost was tested using selective agonists. UMR106.01 cells treated with the cAMP mimetic 8-bromo-cAMP (1 mM) demonstrated similar suppression of Sost as 5 mM PGE 2 -treated cells ( Figure 3C ), whereas 1.3 mM ionomycin treatment significantly increased Sost expression. These data indicate that PGE 2 receptors linked to increased cAMP-Ptger2 or Ptger4-are involved in the capacity for PGE 2 to decrease Sost.
Specific agonists for EP2 (butaprost, [53] ) or EP4 (CAY10580, [54] ) were also tested for their ability to mimic the suppressive effects of PGE 2 on Sost transcription. Butaprost mimicked the ability of PGE 2 to decrease Sost, whereas CAY10580 had no effect on Sost levels ( Figure 4A ). siRNA directed against Ptger2 ( Figure 4B ) or Ptger4 ( Figure 4C ) reproducibly decreased target transcript expression by 60% relative to non-silencing, scrambled siRNAs. Knock-down of Ptger2, but not Ptger4, significantly impaired the ability of PGE 2 to suppress Sost expression ( Figure 4D ), indicating the requirement for the Ptger2 receptor for PGE 2 -specific activation of Wnt signaling. Cycloheximide, but not Actinomycin D, influences PGE 2 suppression of Sclerostin
We examined the transcriptional and translational mechanisms whereby PGE 2 regulates Sost expression. UMR106.01 cells were treated with 5 mM PGE 2 for 3 hours in the presence or absence of the RNA polymerase II inhibitor Actinomycin D (2.5 mg/mL), after which time total RNA was collected and analyzed. The suppressive influence of PGE 2 on Sost transcription was consistent in cells treated with or without actinomycin D (Figure 5A ), indicating that PGE 2 does not promote the degradation of Sost transcript.
Next, UMR106.01 cells were treated with or without 5 mM PGE 2 for 3 hours in the presence or absence of the protein translation inhibitor cycloheximide (CHX; 10 mg/mL). In the absence of PGE 2 , CHX increased Sost transcript ( Figure 5B) ; in cells treated with PGE 2 and CHX, there was no suppressive effect of PGE 2 upon Sost expression, indicating that PGE 2 requires de novo protein synthesis in order to decrease Sost. Similar results were observed after 1 hour of CHX or PGE 2 treatment (data not shown).
Transcriptional regulation of Sost by PGE 2 does not involve Mef2 or BMPs
We have previously demonstrated that the MEF2 family of transcription factors are responsible for sensitizing the Sost distal enhancer ECR5 to PTH [45] . We employed siRNA against Mef2c or Mef2d in order to determine whether these transcription factors are involved in the capacity for PGE 2 to decrease Sost. 48 hours after transfection, expression of Mef2c ( Figure 6A ) and Mef2d ( Figure 6B ) was reduced approximately 70% and 55%, respectively, compared to scrambled siRNA controls. Knockdown of Mef2c or Mef2d did not alter the ability of 5 mM PGE 2 to decrease Sost transcript ( Figure 6C ), suggesting that PGE 2 does not decrease Sost expression by disrupting Mef2 activity.
We, and others, have previously demonstrated the transcriptional influence of bone morphogenetic proteins on Sost: exogenous BMPs or constitutively-active BMP receptor 1A increase Sost expression [50, 51, 55] , whereas dominant-negative BMP Receptor 1A decreases Sost transcription [55] . To examine whether PGE 2 signaling disrupted BMP induction of Sost, UMR106.01 cells co-cultured with 5 mM PGE 2 and BMP-2 (0-500 ng/mL) for 3 hours. BMP-2-treated cells increased Sost expression ( Figure 7A ), whereas co-culture with PGE 2 prevented Sost induction. BMP-2 increased Id1, a direct Smad target gene, independent of PGE 2 ( Figure 7B ), indicating that BMP signaling was unaffected by PGE 2 treatment. These data suggest that PGE 2 decreases Sost transcription independent of the BMP signaling, and hence the effect of PGE2 upon Sost is downstream of BMPs.
PTH does not require prostaglandins to decrease Sost
PTH increases COX-2 expression and subsequent synthesis and release of prostaglandins [56, 57] . Because both PTH and PGE 2 decrease Sost transcription through cAMP/PKA mechanisms, we next examined whether the capacity for PTH to decrease Sost required prostaglandins. Cells were treated for 24 hours in reduced serum (2%) conditions in the presence of 0.05% DMSO or 1 mM indomethacin; thereafter, a subset of cells were treated for 24 hours in the presence of 100 nM hPTH . As shown in Figure 8 , there was a similar decrease in Sost expression in cells treated with PTH with or without indomethacin co-treatment. Thus, PTH does not require prostaglandins to decrease Sost transcription, suggesting that PTH and PGE 2 function through independent, parallel pathways that converge upstream of Sclerostin's transcriptional regulation. 
Discussion
Sclerostin is a robust inhibitor of bone formation, such that its absence leads to increased bone formation, and in high amounts it causes bone loss. Thus, regulation of its expression, as well as that of other potent skeletally anabolic or catabolic proteins, is under intensive investigation as a therapy for those afflicted with osteoporosis, or as a means of hastening fracture repair. Indeed, a monoclonal antibody which inhibits Sclerostin function has already been shown to increase bone formation and strength in ovariectomized rats beyond that of non-ovariectomized controls [58] and in aged male rats [59] . Despite its clinical importance in an aging population, the molecular mechanisms controlling Sclerostin expression are only beginning to be unraveled [43, 45] . Within this work, we demonstrate that PGE 2 , a paracrine signaling agent with diverse effects on skeletal homeostasis, decreases Sost transcription through the EP2 receptor subclass (encoded by Ptger2). Reductions in Sost transcription by PGE 2 was shown to involve cAMP and PKA, de novo protein synthesis, and to occur independently of BMP or MEF2 signaling.
PGE 2 decreases Sost expression via PKA and Ptger2
We observed rapid suppression of Sost by PGE 2 between 50 nM-5 mM, with a calculated IC 50 of 41 nM (data not shown). Reductions in Sost transcript in response to PGE 2 were rapid, occurring within 1 hr of PGE 2 addition, and were sustained, remaining at 30% expression compared to vehicle-treated samples after 24 hours of culture. These results are similar to in vivo calvarial and in vitro cell culture models treated with PTH [43] , as well as murine models of constitutively-active PTHR1 receptor [44, 60] .
Osteoblastic cells express all Ptger receptor genes [61, 62] , suggesting that PGE 2 can exert biological effects through both cAMP and Ca 2+ i signaling pathways. Much of the anabolic effect of PGE 2 is mediated through cAMP via EP2 and EP4 [63] . The cAMP analogue 8-bromo-cAMP mimicked the effect of PGE 2 upon Sost transcription. Inhibition of PLC/IP 3 with U73122 did not prevent PGE 2 from decreasing Sost, indicating that this pathway is not obligate. Interestingly, the calcium ionophore, ionomycin, significantly increased Sost transcription nearly 5-fold over vehicle controls after 3 hours of treatment. This would suggest stimulation of MEF2 transcriptional activity in response to increased Ca 2+ i , as has been shown in skeletal muscle fibers [64, 65] . Keller and Kneissel have shown a modest decrease in Sost transcription in response to a similar dose of ionomycin [43] , but they measured Sost levels after 24 hours of ionomycin treatment (rather than 3 hours, as in the study herein). Whether these contrasting results are due to timing of ionomycin treatment, or are secondary to prolonged cellular stress due to supra-physiologic Ca 2+ i [66] , remains to be elucidated. The requirement for cAMP/PKA to decrease Sost thus implicated either EP2 or EP4 receptor. Butaprost, a selective agonist for EP2 [67] , decreased Sost transcription by 70%, whereas CAY10580, an EP4 agonist [54] , had no significant effect upon Sost levels. The EP2 receptor was further implicated in mediating the suppressive effects of PGE 2 , as siRNA directed against Ptger2, but not scrambled or Ptger4 siRNA, prevented PGE 2 -induced decreases in Sost. In total, these data indicate that PGE 2 signals through EP2 to decrease Sost expression.
PGE 2 and PTH decrease Sost through parallel pathways
PTH has also been shown to increase COX-2 expression and PG release [56, 57] . Because PTH and PGE 2 are both capable of mobilizing the same second messengers (cAMP and IP 3 ), and because both PTH and PGE 2 decreased Sost transcription through similar mechanisms involving cAMP and MEF2, we examined whether PTH required PGE 2 (or other PGs) in order to decrease Sost. Inhibition of COX-1 and COX-2 function with 1 mM indomethacin increased Sost expression (data not shown), indicating tonic suppression of Sost by endogenously-produced prostaglandins. Cells treated with both PTH and indomethacin continued to demonstrate suppression of Sost, indicating that PTH does not require prostaglandins to decrease Sost levels in mature osteoblastic cells.
There are several distinctions that must be made regarding Sost regulation by PTH and PGE 2 . Keller and Kneissel [43] demonstrated that PTH rapidly decreases Sost expression in UMR106.01 cells through a cyclic AMP-dependent pathway. Leupin et al. identified the MEF2 family of transcription factors as a requirement for driving bone-specific Sost expression, and as a target of PTH [45] . Within, we demonstrate that PGE 2 , like PTH, decreases Sost in a cyclic AMP-dependent pathway. While PTH decreases Sost expression through unknown interactions with MEF2C and MEF2D, we continued to observe Sost suppression in cells transfected with Mef2c or Mef2d siRNA, demonstrating one key difference between PGE 2 and PTH. Similarly, inhibition of de novo protein synthesis with cycloheximide maintains PTH suppression of Sost [43] , whereas cycloheximide prevented PGE 2 reductions in Sost. These data indicate that, while both PGE 2 and PTH use cAMP to decrease Sost, there is divergence downstream from cAMP/PKA in the signaling pathways utilized by PTH or PGE 2 for Sost suppression.
Current FDA-approved therapies for combating osteoporosis are limited to drugs, like bisphosphonates, that inhibit bone resorption. Intermittent PTH is the only FDA-approved therapy that promotes bone formation, although treatment is currently limited to 18 months. The sclerosing bone dysplasias sclerosteosis and van Buchem disease are caused by decreased or absent Sclerostin expression, and thereby implicate Sclerostin as a very potent inhibitor of bone formation. Thus, mechanisms for manipulating Sost expression may likely provide a powerful means of increasing bone mass. Within, we have elucidated a novel mechanism of Sclerostin regulation. Continued efforts to modulate its expression and/or activity will likely allow for novel anabolic agents for conditions of bone loss.
Materials and Methods
Cell culture-UMR106.01 cells, which express phenotypic markers of mature osteoblasts [68] , were cultured in MEM with Earle's Salts (Invitrogen) supplemented with 10% fetal bovine serum (FBS; Invitrogen) and 1% penicillin and streptomycin (P&S; Invitrogen). Cells were routinely sub-cultured, using 0.05% trypsin/EDTA when 80-90% confluent; for experiments, cells were seeded into 35 mm 2 dishes at 5 k/cm 2 , and experiments were performed two days thereafter.
Chemicals and reagents-PGE 2 and PGF 2a (Cayman Chemical) were dissolved in DMSO as stock concentrations of 10 mM. Human PTH(1-34) (Bachem) was dissolved in HBSS+0.1% BSA and stored at 100 mM aliquots. H-89 or 8-brcAMP (EMD Biosciences) were dissolved in sterile water; U73122, ionomycin (both EMD Biosciences), butaprost, or CAY10580 (both Cayman Chemical) were dissolved in DMSO.
Quantitative PCR-At the indicated time, cells were washed with PBS and total RNA was collected using RNeasy Mini kit (Qiagen). Total RNA (200-1000 ng) was reverse-transcribed with QuantiTect Reverse Transcription Kit (Qiagen), which includes a genomic DNA elimination step. qPCR was performed using QuantiFast Probe PCR Kit (Qiagen) on a MastercyclerH realplex2 (Eppendorf). Proprietary primer and TaqMan probe sets were purchased from Applied Biosystems. Amplification conditions were 95uC for 3 minutes, followed by 40 cycles at 95uC for 3 seconds and 60uC for 30 seconds. Quantitative PCR results were normalized to loading control (Rpl32 or Tbp) transcript level to yield DC t , then normalized to control conditions to generate DDC t . Relative or fold change in expression was subsequently calculated using the formula 2 2DCt or 2 2DDCt , as described in [69] . Dkk1 ELISA-For measurement of Dkk1 protein production, cells were prepared as described above and cultured for 24 hours in 0.05% DMSO or 5 mM PGE 2 . Conditioned media and whole cell protein lysates were collected and frozen at 220 C until analysis. Dkk1 protein levels in conditioned media were analyzed using a commercially available ELISA against murine Dkk1 (R & D Systems), and results were normalized to whole cell protein concentration.
siRNA-small, interfering RNA against Ptger2, Ptger4, Mef2c, and Mef2d was purchased from Qiagen, as was scrambled, nonsilencing control. Cells were seeded at a density of 40,000 cells per well in a 24-well plate in media supplemented with 10% FBS and 1% P/S. 30 minutes thereafter, 50 nM scrambled, non-silencing or Ptger2 was prepared with HiperFect (Qiagen) in 100 mL of serum-and antibiotic-free media. 20 minutes later, siRNA/ HiperFect/media was overlayed on top of the cells, which were returned to the incubator. Experiments were performed 48 hours later.
Statistical analysis-Each data set was acquired a minimum of three times, in duplicate. qPCR data were first analyzed relative to the internal control Rpl32, then normalized to vehicle control, in order to minimize inter-experimental variation. Results are expressed as mean6standard error of the mean. Data were analyzed by Kruskal-Wallis or ANOVA followed by Dunnet or Tukey post-hoc tests where appropriate. p,0.05 was considered statistically significant.
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